

Abstract of the Disclosure

The present invention is directed to a pharmaceutical composition containing
5 a cancer-treating effective amount of a class of prostacyclin derivatives, and a
pharmaceutically acceptable carrier, and to kits and methods of employing the same
for the treatment of cancer.